Inspira to Unveil HYLA™ Real-Time Blood Sensor at U.S. ELSO; 97.35% Accuracy Confirmed
Inspira Technologies (NASDAQ: IINN) announced the upcoming debut of its HYLA blood sensor at the U.S. ELSO Annual Conference in Washington, D.C., from September 27-30, 2025. The sensor has demonstrated 97.35% accuracy compared to standard blood gas analyzers.
During the conference, management will conduct meetings with key decision-makers from global medical device companies and hospital networks to discuss commercialization and strategic partnerships. The company will also showcase its FDA-cleared ART100 system, demonstrating its comprehensive platform of life-support and monitoring solutions.
Inspira Technologies (NASDAQ: IINN) ha annunciato il prossimo debut del suo sensore sanguigno HYLA durante la US ELSO Annual Conference a Washington, D.C., dal 27 al 30 settembre 2025. Il sensore ha dimostrato una precisione del 97,35% rispetto agli analizzatori standard di gas nel sangue.
Durante la conferenza, la direzione terrà incontri con decisori chiave provenienti da aziende globali di dispositivi medici e reti ospedaliere per discutere della commercializzazione e delle partnership strategiche. L'azienda presenterà anche il suo sistema ART100 approvato dalla FDA, evidenziando la sua piattaforma completa di soluzioni per il supporto vitale e il monitoraggio.
Inspira Technologies (NASDAQ: IINN) anunció el próximo debut de su sensor de sangre HYLA en la Conferencia Anual de ELSO de EE. UU. en Washington, D.C., del 27 al 30 de septiembre de 2025. El sensor ha demostrado una precisión del 97,35% en comparación con los analizadores estándar de gases en sangre.
Durante la conferencia, la dirección llevará a cabo reuniones con decisores clave de empresas globales de dispositivos médicos y redes hospitalarias para discutir la comercialización y asociaciones estratégicas. La empresa también mostrará su sistema ART100 aprobado por la FDA, demostrando su plataforma integral de soluciones de soporte vital y monitoreo.
Inspira Technologies (NASDAQ: IINN)은 2025년 9월 27일부터 30일까지 워싱턴 D.C.에서 열리는 미국 ELSO 연차대회에서 HYLA 혈액 센서의 다가오는 데뷔를 발표했습니다. 이 센서는 표준 혈액 가스 분석기와 비교하여 97.35%의 정확도를 입증했습니다.
회의 기간 동안 경영진은 글로벌 의료기기 기업 및 병원 네트워크의 주요 의사결정권자들과 만나 상용화 및 전략적 파트너십에 대해 논의할 예정입니다. 또한 FDA 승인 ART100 시스템을 선보이며 생명지지 및 모니터링 솔루션의 포괄적 플랫폼을 시연합니다.
Inspira Technologies (NASDAQ : IINN) a annoncé la prochaine mise en avant de son capteur sanguin HYLA lors de la conférence annuelle ELSO américaine à Washington, D.C., du 27 au 30 septembre 2025. Le capteur a démontré une précision de 97,35 % par rapport aux analyseurs d’échantillons sanguins standards.
Pendant la conférence, la direction mènera des réunions avec les décideurs clés des entreprises mondiales de dispositifs médicaux et des réseaux hospitaliers pour discuter de la commercialisation et de partenariats stratégiques. L’entreprise présentera également son système ART100 approuvé par la FDA, démontrant sa plateforme complète de solutions d’assistance vitale et de surveillance.
Inspira Technologies (NASDAQ: IINN) kündigte den kommenden Start seines HYLA-Blut-Sensors auf der US-ELSO-Hauptkonferenz in Washington, D.C., vom 27. bis 30. September 2025 an. Der Sensor zeigte eine Genauigkeit von 97,35% im Vergleich zu Standard-Blutgasanalysatoren.
Während der Konferenz wird das Management Treffen mit wichtigen Entscheidungsträgern globaler medizinischer Geräteunternehmen und Krankenhausnetzwerke abhalten, um über Kommerzialisierung und strategische Partnerschaften zu sprechen. Das Unternehmen wird außerdem sein FDA-zugelassenes ART100-System vorstellen und seine umfassende Plattform aus Lebensunterstützungs- und Überwachungslösungen demonstrieren.
Inspira Technologies (نظراً لـ IINN) أعلنت عن الظهور القادم لجهاز استشعار الدم HYLA في المؤتمر السنوي لـ ELSO الأمريكي في واشنطن العاصمة، من 27 إلى 30 سبتمبر 2025. أظهر المستشعر دقة تبلغ 97.35% مقارنةً بمحللات غازات الدم القياسية.
خلال المؤتمر، ستعقد الإدارة اجتماعات مع صانعي القرار الرئيسيين من شركات الأجهزة الطبية العالمية وشبكات المستشفيات لمناقشة التسويق والشراكات الاستراتيجية. كما ستعرض الشركة نظام ART100 المعتمد من FDA، مبيّنة منصتها الشاملة لحلول دعم الحياة والمراقبة.
Inspira Technologies (纳斯达克: IINN) 宣布将在美国 ELSO 年会于华盛顿特区举行，HYLA 血液传感器 即将首次亮相，时间为 2025 年 9 月 27-30 日。该传感器在与标准血气分析仪相比时显示出 97.35% 的准确性。
在会议期间，管理层将与全球医疗器械公司及医院网络的关键决策者举行会谈，讨论商业化与战略伙伴关系。公司还将展示其 FDA 批准的 ART100 系统，展示其全方位的生命支持与监测解决方案平台。
- HYLA blood sensor achieved impressive 97.35% accuracy compared to standard analyzers
- Management securing meetings with key decision-makers for potential commercialization partnerships
- Company already has FDA-cleared ART100 system in its portfolio
- Product still in pre-commercial phase with no established partnerships yet
Insights
Inspira's HYLA blood sensor shows impressive 97.35% accuracy, positioning it for potential industry adoption as they pursue commercialization partnerships.
Inspira Technologies is making a strategic move by unveiling its HYLA blood sensor at the U.S. ELSO Annual Conference, the premier global gathering for extracorporeal life support professionals. This timing is particularly significant as it follows their recent announcement of the sensor's 97.35% accuracy compared to standard blood gas analyzers – a metric that suggests clinical viability.
The HYLA represents a potentially disruptive advancement in real-time blood monitoring. Current standard blood gas analysis typically requires blood draws and laboratory processing, creating delays between sampling and clinical decision-making. A real-time sensor with high accuracy could dramatically improve critical care response times and potentially patient outcomes, especially in intensive care and during extracorporeal membrane oxygenation (ECMO) procedures.
The planned meetings with global medical device companies and hospital networks indicate Inspira is now pivoting from R&D to commercialization. For medical devices, these partnership discussions are crucial steps toward market entry, as established distribution channels and hospital relationships significantly impact adoption rates.
The concurrent showcase of their FDA-cleared ART100 system suggests Inspira is building a comprehensive platform approach rather than offering isolated products. This ecosystem strategy typically creates stronger market positioning and higher barriers to competitive entry.
However, the path from impressive accuracy metrics to widespread clinical adoption remains challenging. The company will need to demonstrate real-world performance, cost-effectiveness, and workflow integration advantages to convert interest into commercial traction. These upcoming high-level meetings at ELSO may prove pivotal in determining the HYLA's commercial trajectory.
RA'ANANA, Israel, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira," “Inspira Technologies,” or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced it will present its HYLA blood sensor (“HYLA”) to the global medical community for the first time. The presentation will take place at the U.S. ELSO Annual Conference in Washington, D.C., between September 27–30, 2025.
This official unveiling follows the Company’s recent announcement of the HYLA sensor’s performance data, which demonstrated
Alongside the HYLA presentation, Inspira’s management is scheduled to conduct high-level meetings with decision-makers from leading global medical device companies and hospital networks. These meetings are aimed at advancing discussions around commercialization and strategic partnerships for the HYLA platform.
Dagi Ben-Noon, Chief Executive Officer of Inspira Technologies, stated: “After years of intensive development and achieving outstanding accuracy results, we are incredibly proud to bring the HYLA to the world stage at ELSO. This marks a transition from internal validation to engaging directly with key opinion leaders and commercial partners who can help us make this technology the new standard of care. We look forward to demonstrating how the HYLA can empower clinicians and save lives.”
Inspira will also be showcasing its FDA-cleared ART100 system at the conference, highlighting the Company's comprehensive platform of advanced life-support and monitoring solutions.
About Inspira Technologies
Inspira Technologies is a commercial-stage medical device company specializing in advanced respiratory support and real-time blood monitoring solutions. The Company’s U.S. Food and Drug Administration -cleared INSPIRA™ ART100 system is approved for cardiopulmonary bypass in the U.S. and ECMO (Extracorporeal Membrane Oxygenation) procedures outside the U.S and serves as a foundation for the development of the INSPIRA ART500, a next-generation system designed to deliver oxygenation while patients remain awake and spontaneously breathing. Inspira Technologies is also advancing HYLA™, a proprietary blood sensor platform offering continuous, non-invasive monitoring. With multiple cleared products, a growing IP portfolio, and strategic streamlining of its operations, Inspira Technologies is increasingly positioned as an attractive platform within the life-support and MedTech landscape. The Company’s recent internal shifts may reflect broader alignment with long-term industry trends, including consolidation, cross-sector collaboration, and potential strategic partnerships. For more information, visit: https://inspira-technologies.com
Forward-Looking Statement Disclaimer
This press release contains express or implied forward-looking statements pursuant to U.S. Federal securities laws. These forward-looking statements are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. For example, the Company is using forward-looking statements when it discusses its belief that the ELSO conference represents the ideal platform to showcase this new technology, the aim of the prospective meetings at the ELSO conference, the belief that the participation in the ELSO conference marks a transition from internal validation to engaging directly with key opinion leaders and commercial partners, and the prospective showcasing of the ART100 system at the conference. These forward-looking statements and their implications are based solely on the current expectations of the Company's management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in the Company's annual report on Form 20-F for the fiscal year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission (the "SEC"), which is available on the SEC's website at www.sec.gov.
Company Contact
Inspira Technologies – Media Relations
Email: info@inspirao2.com
Phone: +972-9-9664485
FAQ
What accuracy rate did Inspira's HYLA blood sensor achieve in testing?
When will Inspira Technologies (NASDAQ: IINN) present its HYLA blood sensor?
What products will Inspira Technologies showcase at the ELSO conference?
What is the purpose of Inspira's meetings at the ELSO conference?
Has the HYLA blood sensor received FDA clearance?
